Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Abstract ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2022-08, Vol.75 (1), p.e525-e528
Main Authors: FitzGerald, Richard, Dickinson, Laura, Else, Laura, Fletcher, Thomas, Hale, Colin, Amara, Alieu, Walker, Lauren, Penchala, Sujan Dilly, Lyon, Rebecca, Shaw, Victoria, Greenhalf, William, Bullock, Katie, Lavelle-Langham, Lara, Reynolds, Helen, Painter, Wendy, Holman, Wayne, Ewings, Sean, Griffiths, Gareth, Khoo, Saye
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Brief Report
COVID-19 Drug Treatment
Cytidine - analogs & derivatives
Humans
Hydroxylamines
Nucleosides
Parents
Prodrugs - therapeutic use
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P 
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciac199